CN103130890B - Human papillomavirus (HPV) 16E7 monoclonal antibody and relevant hybridoma cell strain and application thereof - Google Patents
Human papillomavirus (HPV) 16E7 monoclonal antibody and relevant hybridoma cell strain and application thereof Download PDFInfo
- Publication number
- CN103130890B CN103130890B CN201110384361.7A CN201110384361A CN103130890B CN 103130890 B CN103130890 B CN 103130890B CN 201110384361 A CN201110384361 A CN 201110384361A CN 103130890 B CN103130890 B CN 103130890B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- hpv16e7
- hpv
- antibody
- specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 32
- 241000701806 Human papillomavirus Species 0.000 title abstract description 26
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 238000002965 ELISA Methods 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- 238000003018 immunoassay Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000699670 Mus sp. Species 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 3
- 238000011532 immunohistochemical staining Methods 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 2
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 37
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 12
- 201000010881 cervical cancer Diseases 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 12
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 102000037865 fusion proteins Human genes 0.000 abstract description 3
- 108020001507 fusion proteins Proteins 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 3
- 239000000090 biomarker Substances 0.000 abstract description 2
- 230000000711 cancerogenic effect Effects 0.000 abstract description 2
- 231100000315 carcinogenic Toxicity 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000005406 washing Methods 0.000 description 14
- 238000012797 qualification Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 10
- 241001494479 Pecora Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000011895 specific detection Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 101100049401 Human papillomavirus type 16 L2 gene Proteins 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- 101150027802 L2 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000007428 ovarian mucinous adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Antibody | Hypotype |
8E5 | IgG2b |
8C10 | IgG2b |
8G9 | IgG1 |
8B12 | IgG1 |
1F6 | IgG1 |
1A5 | IgG2a |
3A5 | IgG2b |
3G5 | IgG2b |
4C8 | IgG3 |
4G1 | IgG2a |
4G5 | IgG1 |
6F2 | IgG2a |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110384361.7A CN103130890B (en) | 2011-11-28 | 2011-11-28 | Human papillomavirus (HPV) 16E7 monoclonal antibody and relevant hybridoma cell strain and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110384361.7A CN103130890B (en) | 2011-11-28 | 2011-11-28 | Human papillomavirus (HPV) 16E7 monoclonal antibody and relevant hybridoma cell strain and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103130890A CN103130890A (en) | 2013-06-05 |
CN103130890B true CN103130890B (en) | 2015-02-25 |
Family
ID=48491387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110384361.7A Active CN103130890B (en) | 2011-11-28 | 2011-11-28 | Human papillomavirus (HPV) 16E7 monoclonal antibody and relevant hybridoma cell strain and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103130890B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105504049B (en) * | 2014-09-26 | 2019-07-05 | 艾托金生物医药(苏州)有限公司 | The relevant HPV E7 protein monoclonal antibody of cervical carcinoma and its application |
CN106366186B (en) * | 2015-07-21 | 2020-03-24 | 艾托金生物医药(苏州)有限公司 | Monoclonal antibody for identifying HPV16 positive tumor cells and application thereof |
CN105801691B (en) * | 2016-03-29 | 2019-05-03 | 上海市普陀区中心医院 | A kind of HPV16E7 monoclonal antibody and its preparation method and application |
CN106397583A (en) * | 2016-12-06 | 2017-02-15 | 亳州市新健康科技有限公司 | POCT (point-of-care testing) fluorescent quantitative test kit for HPV16 type E7 protein and application thereof |
WO2018102982A1 (en) * | 2016-12-06 | 2018-06-14 | 亳州市新健康科技有限公司 | Poct fluorescence quantitative detection kit for hpv16 e7 protein and application thereof |
CN109053879B (en) * | 2018-08-22 | 2020-12-25 | 深圳市宝安区中心医院 | scFv antibody for treating cervical cancer and application thereof |
CN110196332A (en) * | 2019-05-22 | 2019-09-03 | 艾托金生物医药(苏州)有限公司 | A kind of method and its application detecting more hypotype HPV E7 albumen |
CN112430583B (en) * | 2020-10-30 | 2022-02-15 | 武汉呵尔医疗科技发展有限公司 | Monoclonal antibody against HPV E7, cell strain and application thereof |
CN112362874B (en) * | 2020-10-30 | 2024-02-09 | 武汉呵尔医疗科技发展有限公司 | Cervical cancer screening kit |
CN112458061B (en) * | 2020-10-30 | 2022-03-22 | 武汉呵尔医疗科技发展有限公司 | Monoclonal antibody against HPV E6, cell strain and application thereof |
CN115112885B (en) * | 2022-06-18 | 2023-07-28 | 杭州爱光健康科技有限公司 | HPV detection kit and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736318A (en) * | 1995-03-17 | 1998-04-07 | President And Fellows Of Harvard College | Method and kit for evaluating human papillomavirus transformed cells |
US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
-
2011
- 2011-11-28 CN CN201110384361.7A patent/CN103130890B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736318A (en) * | 1995-03-17 | 1998-04-07 | President And Fellows Of Harvard College | Method and kit for evaluating human papillomavirus transformed cells |
US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
Also Published As
Publication number | Publication date |
---|---|
CN103130890A (en) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103130890B (en) | Human papillomavirus (HPV) 16E7 monoclonal antibody and relevant hybridoma cell strain and application thereof | |
CN103254307B (en) | HPV18E7 monoclonal antibody, hybridoma cell strain and application | |
CN105532647B (en) | Menses save the isolated culture method of liquid and its application, menses source endometrial stem cells | |
CN112724252B (en) | Preparation method and application of echinococcus multilocularis antigen monoclonal antibody | |
CN104480062A (en) | Separation and culture method for different cellular components of human mammary tissue | |
CN103243074A (en) | Human colorectal adenocarcinoma tumor cell line as well as preparation method and application thereof | |
CN109082413B (en) | Anti-human IgG monoclonal antibody, hybridoma cell strain and application thereof | |
CN110079501A (en) | Mouse breast cancer circulating tumor cell system and its method for building up | |
CN103923212A (en) | EHD2 antibody and application of EHD2 antibody to preparation of immunohistochemical detection reagent for breast cancer | |
CN111454990B (en) | Human jugular auxiliary nerve ganglionic tumor immortalized cell strain and application thereof | |
CN102443060B (en) | Anti-HPV (human papilloma virus) antibody and preparation method and application thereof | |
CN102220285B (en) | Monoclonal antibody of outer membrane protein of chlamydia abortus and application thereof | |
CN103571796B (en) | Chicken interleukin-10 monoclonal antibodies and preparation method and application thereof | |
CN103060421A (en) | Autophagy monitoring method for fat cells | |
CN102559605A (en) | Orf virus protein ORFV059 monoclonal antibody hybridoma A3 and monoclonal antibody | |
CN105693828A (en) | Novel EB (Epstein-Barr) virus EBNA1 epitope peptide and application thereof in diagnosis, treatment and prevention of EBV related diseases | |
CN105132376B (en) | One can the how individual epitopes of specific recognition HBsAg monoclonal antibody and its application | |
CN109709330B (en) | Foot-and-mouth disease virus competition ELISA detection kit | |
CN113355291A (en) | Monoclonal antibody of mycoplasma filiformis subspecies P0071 protein and application thereof | |
CN112210006A (en) | Mouse anti-human AFP monoclonal antibody and application | |
CN109400712A (en) | The preparation method and applications of third generation LMP1 CAR-T cell | |
CN104945496A (en) | Polypeptide and application thereof in preparing and purifying EHD2-specific antibody | |
CN104945506A (en) | Immunohistochemical reagent for mammary cancer diagnosis and prognosis judgment | |
CN105238763A (en) | Anti-PR protein monoclonal antibody hybridomas cell, anti- PR monoclonal antibody generated by same and application | |
CN101759780B (en) | Soluble liver antigen T cell epitope and detection kit prepared thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: AITUOJIN BIOLOGICAL MEDICINE (SUZHOU) CO., LTD. Free format text: FORMER OWNER: CHANG XIAOJIA Effective date: 20130520 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214434 WUXI, JIANGSU PROVINCE TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130520 Address after: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 B3 No. 218 building 6 floor Applicant after: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Address before: 214434 No. 85 sanding Road, Wuxi, Jiangsu, Jiangyin Applicant before: Chang Xiaojia |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: HPV16E7 monoclonal antibody, related hybridoma cell line and Application Effective date of registration: 20211020 Granted publication date: 20150225 Pledgee: Jiangsu Suzhou Rural Commercial Bank Co.,Ltd. science and Technology Financial Industrial Park sub branch Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2021320010426 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20150225 Pledgee: Jiangsu Suzhou Rural Commercial Bank Co.,Ltd. science and Technology Financial Industrial Park sub branch Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2021320010426 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: HPV16E7 monoclonal antibody, related hybridoma cell lines and applications Granted publication date: 20150225 Pledgee: Suzhou Beiming Intelligent Manufacturing Co.,Ltd. Pledgor: ATTOGEN BIOMEDICAL (SUZHOU) Inc.,Ltd. Registration number: Y2024990000122 |